BioNexus Gene Lab Corp.
BGLC | NASDAQ
$1.48
-$0.02 (-1.33%)
Sep 22, 2026, 11:47 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -2.45 | -3.11 | -3.46 | -456 | 482.45 | 206.33 |
PEG Ratio | -0.03 | 0.08 | -0.01 | 3.10 | -8.23 | -0.05 |
PS Ratio | 0.99 | 0.52 | 0.93 | 15.03 | 27.30 | 19.89 |
PB Ratio | 0.85 | 0.60 | 0.95 | 24.65 | 50.81 | 34 |
P/FCF Ratio | -3.91 | -2.03 | -4.78 | 330.09 | 60.82K | 1.73K |
P/OCF Ratio | -3.99 | -2.23 | -5.18 | 297.69 | 39.83K | 409.83 |
OCF/S Ratio | -24.76 | -23.49 | -18.02 | 5.05 | 0.07 | 4.85 |
Debt / Equity Ratio | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 | 0.02 |
Quick Ratio | 9.16 | 3.10 | 4.24 | 2.52 | 2.39 | 2.02 |
Current Ratio | 10.46 | 3.81 | 4.93 | 3 | 3.04 | 2.37 |
Asset Turnover | 0.80 | 0.91 | 0.86 | 1.25 | 1.40 | 1.13 |
Interest Coverage | -161.62 | -74.42 | -186.20 | -23.33 | 81.39 | 112.60 |
Return on Equity | -34.64% | -19.20% | -27.22% | -5.34% | 10.47% | 16.42% |
Return on Assets | -32.26% | -15.32% | -23.06% | -4.07% | 7.85% | 10.82% |
Return on Invested Capital | -35.93% | -18.44% | -26.42% | -4.31% | 10.44% | 16.26% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 14.62% | 13.56% | 13.61% | 11.52% | 16.42% | 15.10% |
Net Profit Margin | -40.20% | -16.81% | -26.91% | -3.26% | 5.62% | 9.61% |
Pretax Profit Margin | -40.20% | -16.77% | -26.69% | -2.78% | 7.80% | 11.08% |
Operating Profit Margin | -42.54% | -16.55% | -26.54% | -2.66% | 7.90% | 11.18% |
FCF Margin | -25.26% | -25.88% | -19.55% | 4.55% | 0.04% | 1.15% |
EBITDA Margin | -37.67% | -14.94% | -25.43% | -1.70% | 8.71% | 12.08% |
Add to Watchlist
Select watchlists to add or remove BGLC